High HIV incidence among young women in South Africa: Data from a large prospective study

Thesla Palanee-Phillips, Helen V Rees, Kate B Heller, Khatija Ahmed, Joanne Batting, Ivana Beesham, Renee Heffron, Jessica Justman, Heeran Makkan, Timothy D Mastro, Susan A Morrison, Nelly Mugo, Gonasagrie Nair, James Kiarie, Neena M Philip, Melanie Pleaner, Krishnaveni Reddy, Pearl Selepe, Petrus S Steyn, Caitlin W Scoville, Jenni Smit, Katherine K Thomas, Deborah Donnell, Jared M Baeten, ECHO Trial Consortium, Thesla Palanee-Phillips, Helen V Rees, Kate B Heller, Khatija Ahmed, Joanne Batting, Ivana Beesham, Renee Heffron, Jessica Justman, Heeran Makkan, Timothy D Mastro, Susan A Morrison, Nelly Mugo, Gonasagrie Nair, James Kiarie, Neena M Philip, Melanie Pleaner, Krishnaveni Reddy, Pearl Selepe, Petrus S Steyn, Caitlin W Scoville, Jenni Smit, Katherine K Thomas, Deborah Donnell, Jared M Baeten, ECHO Trial Consortium

Abstract

Introduction: South Africa has the highest national burden of HIV globally. Understanding drivers of HIV acquisition in recently completed, prospective studies in which HIV was an endpoint may help inform the strategy and investments in national HIV prevention efforts and guide the design of future HIV prevention trials. We assessed HIV incidence and correlates of incidence among women enrolled in ECHO (Evidence for Contraceptive Options and HIV Outcomes), a large, open-label randomized clinical trial that compared three highly effective. reversible methods of contraception and rates of HIV acquisition.

Methods: During December 2015 to October 2018, ECHO followed sexually active, HIV-seronegative women, aged 16-35 years, seeking contraceptive services and willing to be randomized to one of three contraceptive methods (intramuscular depot medroxyprogesterone acetate, copper intrauterine device, or levonorgestrel implant) for 12-18 months at nine sites in South Africa. HIV incidence based on prospectively observed HIV seroconversion events. Cox proportional hazards regression models were used to define baseline cofactors related to incident HIV infection.

Results: 5768 women were enrolled and contributed 7647 woman-years of follow-up. The median age was 23 years and 62.5% were ≤24 years. A total of 345 incident HIV infections occurred, an incidence of 4.51 per 100 woman-years (95%CI 4.05-5.01). Incidence was >3 per 100 woman-years at all sites. Age ≤24 years, baseline infection with sexually transmitted infections, BMI≤30, and having new or multiple partners in the three months prior to enrollment were associated with incident HIV.

Conclusions: HIV incidence was high among South African women seeking contraceptive services. Integration of diagnostic management of sexually transmitted infections alongside delivery of HIV prevention options in health facilities providing contraception services are needed to mitigate ongoing risks of HIV acquisition for this vulnerable population.

Clinical trial registration: ClinicalTrials.gov, number NCT02550067 was the main Clinical Trial from which this secondary, non-randomized / observational analysis was derived with data limited to just South African sites.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. HIV seroincidence by South African…
Fig 1. HIV seroincidence by South African ECHO Trial Site between December 2015 to October 2018.

References

    1. Human Sciences Reseach Council. The Fifth South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: HIV Impact Assessment Summary Report. Cape Town, HSRC Press. 2018.
    1. UNAIDS JUNPoHA. UNAIDS DATA 2019. . 2019.
    1. Simbayi L, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al.. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey. 2019. Epub Cape Town: HSRC Press, 2017.
    1. McDougal JS, Pilcher CD, Parekh BS, Gershy-Damet G, Branson BM, Marsh K, et al.. Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS (London, England). 2005;19 Suppl 2:S25–S30. doi: 10.1097/01.aids.0000172874.90133.7a .
    1. Hofmeyr GJ, Morrison CS, Baeten JM, Chipato T, Donnell D, Gichangi P, et al.. Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). Gates Open Res. 2018;1:17-. doi: 10.12688/gatesopenres.12775.2 .
    1. ECHO Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–13. Epub 2019/06/18. doi: 10.1016/S0140-6736(19)31288-7 .
    1. Beesham I, Welch JD, Heffron R, Pleaner M, Kidoguchi L, Palanee-Phillips T, et al.. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. Journal of the International AIDS Society. 2020;23(5):e25491. doi: 10.1002/jia2.25491
    1. Donnell D, Beesham I, Welch JD, Heffron R, Pleaner M, Kidoguchi L, et al.. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study. The Lancet HIV. 2021;8(8):e495–e501. doi: 10.1016/S2352-3018(21)00048-5
    1. WHO Health Organization Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021.
    1. Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, et al.. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. The New England journal of medicine. 2021;384(12):1089–100. Epub 2021/03/25. doi: 10.1056/NEJMoa2031499 .
    1. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections / King K. Holmes, Ruth Levine and Marcia Weaver. Efficacité du préservatif pour la prévention des infections sexuellement transmissibles: résumé. 2004.
    1. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. The Cochrane database of systematic reviews. 2002;(1):Cd003255. Epub 2002/03/01. doi: 10.1002/14651858.CD003255 .
    1. Mabaso M, Sokhela Z, Mohlabane N, Chibi B, Zuma K, Simbayi L. Determinants of HIV infection among adolescent girls and young women aged 15–24 years in South Africa: a 2012 population-based national household survey. BMC Public Health. 2018;18(1):183. Epub 2018/01/28. doi: 10.1186/s12889-018-5051-3 .
    1. Harrison A, Colvin CJ, Kuo C, Swartz A, Lurie M. Sustained High HIV Incidence in Young Women in Southern Africa: Social, Behavioral, and Structural Factors and Emerging Intervention Approaches. Current HIV/AIDS reports. 2015;12(2):207–15. doi: 10.1007/s11904-015-0261-0 .
    1. Dellar RC, Dlamini S, Karim QA. Adolescent girls and young women: key populations for HIV epidemic control. Journal of the International AIDS Society. 2015;18(2 Suppl 1):19408-. doi: 10.7448/IAS.18.2.19408 .
    1. Swartz A, Colvin C, Harrison A. The Cape Town boyfriend and the Joburg boyfriend: women’s sexual partnerships and social networks in Khayelitsha, Cape Town. Social dynamics. 2016;42(2):237–52. Epub 2016/01/01. doi: 10.1080/02533952.2016.1194591 .
    1. Leclerc-Madlala S. Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability. Aids. 2008;22 Suppl 4:S17–25. Epub 2008/12/17. doi: 10.1097/01.aids.0000341774.86500.53 .
    1. Mah TL, Halperin DT. Concurrent sexual partnerships and the HIV epidemics in Africa: evidence to move forward. AIDS and behavior. 2010;14(1):11–6; dicussion 34–7. Epub 2008/07/24. doi: 10.1007/s10461-008-9433-x .
    1. Mah TL, Maughan-Brown B. Social and cultural contexts of concurrency in a township in Cape Town, South Africa. Cult Health Sex. 2013;15(2):135–47. Epub 2012/11/28. doi: 10.1080/13691058.2012.745951 .
    1. Halperin DT, Epstein H. Concurrent sexual partnerships help to explain Africa’s high HIV prevalence: implications for prevention. Lancet. 2004;364(9428):4–6. Epub 2004/07/06. doi: 10.1016/S0140-6736(04)16606-3 .
    1. Halperin DT, Epstein H. Opinion—Why is HIV prevalence so severe in southern Africa.? The role of multiple concurrent partnerships and lack of male circumcision—implications for HIV prevention. 2007. 2007;8(1). Epub 2007-01-15. doi: 10.4102/sajhivmed.v8i1.630
    1. Kharsany AB, McKinnon LR, Lewis L, Cawood C, Khanyile D, Maseko DV, et al.. Population Prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal, South Africa: Implications for HIV epidemic control. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2020. Epub 2020/06/21. doi: 10.1016/j.ijid.2020.06.046 .
    1. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19(2):61–77. Epub 1992/03/01. .
    1. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis. 2001;28(10):579–97. Epub 2001/11/02. doi: 10.1097/00007435-200110000-00005 .
    1. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al.. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. The Lancet Infectious diseases. 2017;17(12):1303–16. Epub 2017/08/28. doi: 10.1016/S1473-3099(17)30405-X .
    1. Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. Journal of the International AIDS Society. 2019;22 Suppl 6(Suppl Suppl 6):e25355. Epub 2019/08/31. doi: 10.1002/jia2.25355 .
    1. Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al.. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099. Epub 2016/08/24. doi: 10.1371/journal.pmed.1002099
    1. Sugarman J, Celum CL, Donnell D, Mayer KH. Ethical considerations for new HIV prevention trials. The lancet HIV. 2019;6(8):e489–e91. Epub 2019/06/22. doi: 10.1016/S2352-3018(19)30184-5 .
    1. Janes H, Donnell D, Gilbert PB, Brown ER, Nason M. Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. The lancet HIV. 2019;6(7):e475–e82. Epub 2019/05/13. doi: 10.1016/S2352-3018(19)30133-X .

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa